Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.

Cesne, A L; Judson, I; Maki, R; Grosso, F; Schuetze, S; Mehren, M V; Chawla, S P; Demetri, G D; Nieto, A; Tanovic, A; Blay, J-Y

Cesne, A L; Judson, I; Maki, R; Grosso, F; Schuetze, S; Mehren, M V; Chawla, S P; Demetri, G D; Nieto, A; Tanovic, A; Blay, J-Y.

Affiliation

Cesne AL; Department of Medicine, Institut Gustave Roussy, 39/53 rue Camille Desmoulins, FR-94805 Villejuif Cedex, France.

Br J Cancer ; 109(7): 1717-24, 2013 Oct 01.

Article in En | MEDLINE | ID: mdl-24022187

Subject(s)

Antineoplastic Agents, Alkylating/therapeutic use; Dioxoles/therapeutic use; Sarcoma/drug therapy; Sarcoma/mortality; Tetrahydroisoquinolines/therapeutic use; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating/adverse effects; Dioxoles/adverse effects; Disease-Free Survival; Female; Humans; Male; Middle Aged; Retrospective Studies; Tetrahydroisoquinolines/adverse effects; Trabectedin; Treatment Outcome; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sarcoma / Antineoplastic Agents, Alkylating / Tetrahydroisoquinolines / Dioxoles Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2013 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google